Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227285 · ClinicalTrials.gov registry record · Phase 1
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
A Phase 1 study, sponsored by EG 427.
- Not yet
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07227285 is a Phase 1 study that has not yet begun recruiting, run by EG 427. The registered enrollment target is 16 participants.
The verdict
NCT07227285, a Phase 1 study, has not yet begun recruiting, sponsored by EG 427.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.
Interventions
- DRUG EG110A
- OTHER Urodynamics
- OTHER Patient-reported Outcome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-04 |
| Est. Completion | 2031-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227285
The ClinicalTrials.gov registry entry for NCT07227285 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EG 427, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which EG110A is the first listed.
NCT07227285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227285 about?
NCT07227285 is a clinical study titled "Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy". The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in...
What is the current status of trial NCT07227285?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-04. Estimated completion is 2031-04.
What interventions are being tested in trial NCT07227285?
The interventions under investigation include: EG110A (DRUG), Urodynamics (OTHER), Patient-reported Outcome (OTHER).
Who is sponsoring clinical trial NCT07227285?
This trial is sponsored by EG 427, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.